Key clinical point: Once-weekly exenatide was superior to placebo in improving glycemic control and was well tolerated in youth with type 2 diabetes (T2D) who were suboptimally controlled with current treatments. It had a safety profile similar to that in adults.
Major finding: At 24 weeks, the least squares mean change in the glycated hemoglobin level in the exenatide vs placebo group was −0.36% vs 0.49%, respectively, with a between-group difference of −0.85% (P = .012) showing the superiority of exenatide over placebo. Adverse events were reported by 61.0% and 73.9% of participants in the exenatide and placebo groups, respectively.
Study details: Findings are from a multicenter, parallel-group, phase 3 study including 72 patients with T2D suboptimally controlled with current treatments who were randomly assigned to receive once-weekly exenatide (n = 49) or placebo (n = 23).
Disclosures: This study was funded by AstraZeneca. N Shehadeh and O Doehring declared receiving support from AstraZeneca. The other authors declared being employees or holding stocks in AstraZeneca.
Source: Tamborlane WV et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care. 2022;45(8):1833–1840 (Jul 26). Doi: 10.2337/dc21-2275